Skip to main content
Log in

Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript


The aim of this study was to investigate the diagnostic role of the CA 125, ferritin, beta-2 microglobulin (β2 M), and lactic dehydrogenase (LDH) levels in serum and peritoneal fluid (PF) in patients with ovarian neoplasms. Using cross-sectional study design; serum and PF CA 125, ferritin, β2 M, and LDH levels were analyzed in 40 patients with benign ovarian neoplasms (Group 1) and 59 patients with malignant ovarian neoplasms (Group 2) which were evaluated surgically. Serum and PF levels of these markers compared between the groups. Diagnostic role of these markers were determined with receiver operating curve (ROC) analysis. Serum and PF CA 125, ferritin, β2 M, and LDH levels were statistically significant higher in patients with ovarian cancers as compared with benign neoplasms. Among these biomarkers, PF β2 M levels had highest sensitivity and specificity, 76.3 and 85%, respectively with the cut-off value: 2.3 mg/l. This study results indicates that especially PF β2 M and ferritin levels may be valuable for diagnosis of malignant ascites in patients with ovarian neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others


  1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29.

    Article  PubMed  CAS  Google Scholar 

  2. Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011;2011:475983.

    Article  PubMed  Google Scholar 

  3. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384–9.

    Article  PubMed  CAS  Google Scholar 

  4. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267–77.

    Article  PubMed  CAS  Google Scholar 

  5. Molina R, Filella X, Jo J, Ballesta AM. CA 125 in biological fluids. Int J Biol Markers. 1998;13:224–30.

    PubMed  CAS  Google Scholar 

  6. Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ, Huebers HA. Plasma ferritin determination as a diagnostic tool. West J Med. 1986;145(5):657.

    PubMed  CAS  Google Scholar 

  7. Schneider D, Halperin R, Langer R, et al. Peritoneal fluid lactate dehydrogenase in ovarian cancer. Gynecol Oncol. 1997;66:399–404.

    Article  PubMed  CAS  Google Scholar 

  8. Yuce K, Baykal C, Genc C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynecol Oncol. 2001;22(3):228–32.

    CAS  Google Scholar 

  9. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3:952–61.

    Article  PubMed  CAS  Google Scholar 

  10. Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res. 1997;27:95–102.

    Article  PubMed  CAS  Google Scholar 

  11. Cabrera T, López-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother. 2003;52(1):1–9.

    PubMed  CAS  Google Scholar 

  12. Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol. 2000;77:254–7.

    Article  PubMed  CAS  Google Scholar 

  13. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264–5.

    Article  PubMed  CAS  Google Scholar 

  14. Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer. 2002;95(9):1886–93.

    Article  PubMed  Google Scholar 

  15. Tuzun Y, Celik Y, Bayan K, Yilmaz S, Dursun M, Canoruc F. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt? J Int Med Res. 2009;37(1):79–86.

    PubMed  CAS  Google Scholar 

  16. Halperin R, Hadas E, Bukovsky I, Schneider D. Peritoneal fluid analysis in the differentiation of ovarian cancer and benign ovarian tumor. Eur J Gynaecol Oncol. 1999;20(1):40–4.

    PubMed  CAS  Google Scholar 

  17. Yinnon A, Konijn AM, Link G, Moreb J, Hershko C. Diagnostic value of ferritin in malignant pleural and peritoneal effusions. Cancer. 1988;62(12):2564–8.

    Article  PubMed  CAS  Google Scholar 

  18. Tripathi PK, Chatterjee SK. Elevated expression of ferritin H-chain mRNA in metastatic ovarian tumor. Cancer Invest. 1996;14(6):518–26.

    Article  PubMed  CAS  Google Scholar 

  19. Pinto V, Marinaccio M, Garofalo S, Vittoria Larocca AM, Geusa S, Lanzilotti G, et al. Preoperative evaluation of ferritinemia in primary epithelial ovarian cancer. Tumori. 1997;83(6):927–9.

    PubMed  CAS  Google Scholar 

  20. Paydas S, Sargin O, Ozbek S, Gürbüz E. Ferritin levels in malignant effusions: a useful marker?. Eur J Cancer. 1990;26(8):919.

    PubMed  CAS  Google Scholar 

  21. Demirkazik A, Dinçol D, Hastürk S, Arican A, Karaoguz H, Cay F, Içli F. Diagnostic value of ferritin in the differential diagnosis of malignant effusions. Cancer Biochem Biophys. 1998;16(3):243–51.

    PubMed  CAS  Google Scholar 

  22. Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer. 1983;32(5):547–54.

    Article  PubMed  CAS  Google Scholar 

  23. Rolland P, Deen S, Scott I, Durrant L, Spendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res. 2007;13(12):3591–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There are no conflicts of interest.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Umran Kucukgoz Gulec.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kucukgoz Gulec, U., Paydas, S., Guzel, A.B. et al. Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia. Med Oncol 29, 2937–2943 (2012).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: